SiliconInvestor
     Advanced Search   [ sign in ]

sponsor
Sponsor

 Biotech / Medical : Biotech Valuation

 Public Reply | Prvt Reply | Mark as Last Read | FilePrevious 10 | Next 10 | Previous | Next  
To: Ron Perlman who wrote (30829)4/3/2009 1:00:44 PM
From: Jack HartmannRead Replies (1) of 40275
 
There hasn't been any news related to DNDN, but some are pointing to an agenda for the American Urological Association's annual meeting, which indicates the results of the Provenge Trial will be discussed on Apr 28. Provenge is DNDN's prostate cancer drug, and the co previously said they are awaiting the completion of the final analysis of their Impact trial on Provenge, expected by the end of April.
Report TOU ViolationShare This Post
 Public Reply | Prvt Reply | Mark as Last Read | FilePrevious 10 | Next 10 | Previous | Next  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQ
Copyright © 1995-2013 Knight Sac Media. All rights reserved.